The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology: Clinical Practice Guidelines-Anticoagulation During Cardiopulmonary Bypass

被引:43
作者
Shore-Lesserson, Linda [1 ]
Baker, Robert A. [2 ,3 ]
Ferraris, Victor A. [4 ]
Greilich, Philip E. [5 ]
Fitzgerald, David [6 ]
Roman, Philip [7 ]
Hammon, John W. [8 ]
机构
[1] Hofstra Northwell, Zucker Sch Med, Dept Anesthesiol, Hempstead, NY USA
[2] Flinders Univ S Australia, Cardiac Surg Res & Perfus, Adelaide, SA, Australia
[3] Flinders Med Ctr, Adelaide, SA, Australia
[4] Univ Kentucky, Div Cardiovasc & Thorac Surg, Lexington, KY USA
[5] Univ Texas Southwestern Med Ctr Dallas, Dept Anesthesiol & Pain Management, Dallas, TX 75390 USA
[6] Med Univ South Carolina, Div Cardiovasc Perfus, Charleston, SC USA
[7] St Anthony Hosp, Dept Anesthesiol, Lakewood, CO USA
[8] Wake Forest Univ, Sch Med, Dept Cardiothorac Surg, Winston Salem, NC 27109 USA
关键词
HEPARIN-INDUCED THROMBOCYTOPENIA; ACTIVATED CLOTTING TIME; CARDIAC SURGICAL-PATIENTS; OPEN-HEART-SURGERY; RECOMBINANT PLATELET-FACTOR-4; PROTAMINE REVERSAL; COAGULATION TIME; BLOOD-LOSS; INDIVIDUALIZED HEPARIN; HEMOSTATIC ACTIVATION;
D O I
10.1213/ANE.0000000000002613
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Despite more than a half century of "safe" cardiopulmonary bypass (CPB), the evidence base surrounding the conduct of anticoagulation therapy for CPB has not been organized into a succinct guideline. For this and other reasons, there is enormous practice variability relating to the use and dosing of heparin, monitoring heparin anticoagulation, reversal of anticoagulation, and the use of alternative anticoagulants. To address this and other gaps, The Society of Thoracic Surgeons, the Society of Cardiovascular Anesthesiologists, and the American Society of Extracorporeal Technology developed an Evidence Based Workgroup. This was a group of interdisciplinary professionals gathered to summarize the evidence and create practice recommendations for various aspects of CPB. To date, anticoagulation practices in CPB have not been standardized in accordance with the evidence base. This clinical practice guideline was written with the intent to fill the evidence gap and to establish best practices in anticoagulation therapy for CPB using the available evidence. To identify relevant evidence, a systematic review was outlined and literature searches were conducted in PubMed using standardized medical subject heading (MeSH) terms from the National Library of Medicine list of search terms. Search dates were inclusive of January 2000 to December 2015. The search yielded 833 abstracts, which were reviewed by two independent reviewers. Once accepted into the full manuscript review stage, two members of the writing group evaluated each of 286 full papers for inclusion eligibility into the guideline document. Ninety-six manuscripts were included in the final review. In addition, 17 manuscripts published before 2000 were included to provide method, context, or additional supporting evidence for the recommendations as these papers were considered sentinel publications. Members of the writing group wrote and developed recommendations based on review of the articles obtained and achieved more than two thirds agreement on each recommendation. The quality of information for a given recommendation allowed assessment of the level of evidence as recommended by the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Recommendations were written in the three following areas: ( 1) heparin dosing and monitoring for initiation and maintenance of CPB; ( 2) heparin contraindications and heparin alternatives; and ( 3) reversal of anticoagulation during cardiac operations. It is hoped that this guideline will serve as a resource and will stimulate investigators to conduct more research and to expand on the evidence base on the topic of anticoagulation therapy for CPB.
引用
收藏
页码:413 / 424
页数:12
相关论文
共 118 条
[1]  
ADDONIZIO VP, 1987, SURGERY, V102, P796
[2]  
Agarwal Shvetank, 2012, J Anaesthesiol Clin Pharmacol, V28, P106, DOI 10.4103/0970-9185.92458
[3]   Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis [J].
Bakchoul, Tamam ;
Zoellner, Heike ;
Amiral, Jean ;
Panzer, Simon ;
Selleng, Sixten ;
Kohlmann, Thomas ;
Brandt, Sven ;
Delcea, Mihaela ;
Warkentin, Theodore E. ;
Sachs, Ulrich J. ;
Greinacher, Andreas .
BLOOD, 2013, 121 (15) :2821-2827
[4]   Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery [J].
Bennett-Guerrero, E ;
Slaughter, TF ;
White, WD ;
Welsby, IJ ;
Greenberg, CS ;
El-Moalem, H ;
Ortel, TL .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2005, 130 (06) :1567-1572
[5]   Heparin-induced recurrent anaphylaxis [J].
Berkun, Y ;
Haviv, YS ;
Schwartz, LB ;
Shalit, M .
CLINICAL AND EXPERIMENTAL ALLERGY, 2004, 34 (12) :1916-1918
[6]   REVERSAL OF HEPARIN ANTICOAGULATION BY RECOMBINANT PLATELET FACTOR-4 AND PROTAMINE SULFATE IN BABOONS DURING CARDIOPULMONARY BYPASS [J].
BERNABEI, A ;
GIKAKIS, N ;
MAIONE, TE ;
KOWALSKA, MA ;
YAN, Z ;
NIEWIAROWSKI, S ;
EDMUNDS, LH .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1995, 109 (04) :765-771
[7]   Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options [J].
Bircher, A. J. ;
Harr, T. ;
Hohenstein, L. ;
Tsakiris, D. A. .
ALLERGY, 2006, 61 (12) :1432-1440
[8]   Life threatening cardiopulmonary failure in an infant following protamine reversal of heparin after cardiopulmonary bypass [J].
Boigner, H ;
Lechner, E ;
Brock, H ;
Golej, J ;
Trittenwein, G .
PAEDIATRIC ANAESTHESIA, 2001, 11 (06) :729-732
[9]   Comparison of ACT point-of-care measurements: repeatability and agreement [J].
Bosch, YPJ ;
Ganushchak, YM ;
de Jong, DS .
PERFUSION-UK, 2006, 21 (01) :27-31
[10]  
BULL BS, 1975, J THORAC CARDIOV SUR, V69, P674